Trial ISRCTN73765130
Publication Munro A , Lancet, 2021
Primary outcome on the report: Safety and reactogenicity, and immunogenicity. Safety and reactogenicity were determined by the occurrence of solicited, unsolicited adverse events, adverse events of special interest, or serious adverse events following vaccination, as recorded in participant electronic diaries or ascertained at follow-up visits. Immunogenicity outcome was anti-spike protein IgG at day 28 follow-up.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.